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A B S T R A C T
Malaria remains a major disease in the developing world and globally is the most important parasitic
disease causing significant morbidity and mortality. Because of widespread resistance to conventional
antimalarials, including chloroquine (CQ), new drugs are urgently needed. Here we report on the anti-
malarial efficacy, both in vitro and in vivo, of a series of aminoquinoline derivatives with adamantane
or benzothiophene as a carrier. In vitro efficacy was evaluated by a lactate dehydrogenase (LDH) assay
in cultures of a CQ-sensitive (3D7) and CQ-resistant (Dd2) strain of Plasmodium falciparum. Of a series
of 26 screened compounds, 12 that exerted a growth inhibition rate of ≥50% were further examined in
vitro to determine the 50% inhibitory concentration (IC50) values. Nine compounds shown in prelimi-
nary experiments to be non-toxic in vivo were evaluated in C57BL/6 mice infected with Plasmodium berghei
ANKA strain using a modified Thompson test. All nine compounds examined in vivo prolonged the sur-
vival of treated versus untreated mice, four of which afforded ≥60% survival. Most notably, two of these
compounds, both with the adamantane carrier, afforded complete cure (100% survival and parasite clear-
ance). Interestingly, one of these compounds had no in vitro effect against the CQ-resistant P. falciparum
strain. Better in vivo compared with in vitro results suggest a role for compound metabolites rather than
the compounds themselves. The results presented here point to adamantane as a carrier that enhances
the antimalarial potential of aminoquinolines.
© 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
1. Introduction
Malaria, caused by protozoan parasites of the Plasmodium genus,
continues to be a major health problem in the developing world and
is globally the most important parasitic disease causing signifi-
cant morbidity and mortality. Human infections are caused by five
species of the genus, namely Plasmodium falciparum, Plasmodium
vivax, Plasmodium ovale, Plasmodium malariae and Plasmodium
knowlesi. Infection resulting from the bite of an infected female
Anopheles mosquito is characterised by blood and liver stages [1].
The World Health Organization (WHO) estimated 214 million
cases of malaria and 438 000 deaths in 2015 [2], with most of the
deaths caused by P. falciparum. One-half of the global human pop-
ulation, residing in tropical and subtropical areas, is estimated to
be at a risk of infection, but even the other half is facing an increas-
ing number of imported cases, resulting in deaths and health system
burden in non-endemic countries and occasional secondary trans-
mission in areas where malaria has long ago been eradicated [3].
The efficacy of the main conventional antimalarials, including
chloroquine (CQ) and artemisinin, is hampered by widespread drug
resistance. Coupled with the lack of an effective vaccine, this strongly
emphasises the urgent need for novel compounds to treat and
prevent malaria [4,5].
The mechanism of action of CQ, like all quinolones, involves ac-
tivity against the erythrocyte forms of all Plasmodium spp. by
preventing polymerisation of heme through its selective accumu-
lation in the parasite food vacuole (FV). CQ forms stable complexes
with heme and its removal from the FV is prevented by protonation
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[6,7]. Mutations in the P. falciparum CQ resistance transporter (PfCRT)
gene have a central role in CQ resistance. PfCRT is located in the FV
membrane and, when mutated, increases CQ export from the FV
and decreases its concentration inside the parasite [6,8,9].
The aminoquinoline structure is very well known as a moiety
useful for the design and development of new antimalarial agents
[10–14]. Synthetic quinoline derivatives remain the most promis-
ing basis for discovery of new drugs [15], especially if they are
effective against strains of Plasmodium resistant to CQ [16,17], and
4-aminoquinoline derivatives continue to be the most sought after
antimalarial agents for chemical modification [18]. Efforts to develop
new aminoquinolines include overcoming CQ resistance by adding
modifications at the ring or at the side chain, with the main aim
of finding new compounds that are not recognised by mutant trans-
porters and thus cannot be pumped out of the parasite FV.
Recently, the synthesis of a series of aminoquinolines and
tetraoxanes with demonstrated antiplasmodial activity, including
activity both against the liver and blood stages, has been de-
scribed [19]. Here we report on further examination of the
aminoquinoline series in different in vitro model systems and provide
further evidence for the complete curative effect observed in vivo
by two compounds despite, at least in one case, a poor in vitro effect.
2. Materials and methods
2.1. Parasites
Cultures of a chloroquine-sensitive (CQS) 3D7 and a chloroquine-
resistant (CQR) Dd2 strain of P. falciparum were maintained in human
erythrocytes as described previously [20]. For in vitro drug assays,
parasites were synchronised with 5% sorbitol and ring-stage para-
sites were then seeded in 96-well plates to achieve 2% parasitaemia
and 0.75% haematocrit.
In vivo testing was performed using the Plasmodium berghei ANKA
strain maintained through serial intraperitoneal passage in C57BL/6
mice.
2.2. Mice
Female C57BL/6 mice (Medical Military Academy Animal Re-
search Facility, Belgrade, Serbia), weighing 19–21 g, were used.
Groups of four to six animals were housed in the Institute for Medical
Research Animal Facility of the University of Belgrade (Belgrade,
Serbia) under a natural photoperiod and were offered drinking water
and standard feed ad libitum.
2.3. Compounds
A total of 26 experimental aminoquinoline derivatives with
adamantane or benzothiophene as a carrier, synthesised at the
Faculty of Chemistry of the University of Belgrade, were exam-
ined (Table 1).
According to the modifications at the aminoquinoline moiety
structure, the compounds belonged to five groups as follows:
(i) 4-aminoquinoline (AQ) (n = 3 compounds); (ii) 7-chloro-4-
aminoquinoline (ClAQ) (n = 6); (iii) 3-fluoro-4-aminoquinoline (FAQ)
(n = 2); (iv) 3-fluoro-7-chloro-4-aminoquinoline (FClAQ) (n = 8); and
(v) 3-fluoro-7-chloro-2-aminoquinoline (FCl2AQ) (n = 7).
For experimental use in vitro, the compounds were dissolved in
dimethyl sulfoxide (DMSO) at a stock concentration of 50 mM. Com-
pounds were further diluted in complete RPMI 1640 culture medium
so that the final DMSO concentration was ≤0.2%.
Compounds further investigated in vivo were suspended in 0.5%
hydroxyethyl cellulose/0.1% Tween 80 and were administered per
os (p.o.).
2.4. Experimental design
All compounds were screened in vitro by the lactate dehydro-
genase (LDH) assay adapted for Plasmodium [21], and those that at
a defined concentration inhibited proliferation of either Plasmo-
dium strain by ≥50% were titrated to obtain 50% inhibitory
concentration (IC50) values and were examined for in vivo efficacy.
Table 1
Investigated compounds grouped according to modifications at the aminoquinoline moiety.
Group Compound Acronym Compound no. in [19]
AQ N1-(1-adamantylmethyl)-N3-quinolin-4-ylbutane-1,3-diamine, C24H33N3 AQ1 24
N1-[2-(1-adamantyl)ethyl]-N3-quinolin-4-ylbutane-1,3-diamine AQ2 44
N-(1-adamantylmethyl)-N-methyl-N’-quinolin-4-ylpropane-1,3-diamine AQ3 Not previously published






FAQ N1-(1-adamantylmethyl)-N3-(3-fluoroquinolin-4-yl)butane-1,3-diamine FAQ1 26
N1-[2-(1-adamantyl)ethyl]-N3-(3-fluoroquinolin-4-yl)butane-1,3-diamine FAQ2 39















AQ, 4-aminoquinoline; ClAQ, 7-chloro-4-aminoquinoline; FAQ, 3-fluoro-4-aminoquinoline; FClAQ, 3-fluoro-7-chloro-4-aminoquinoline; FCl2AQ, 3-fluoro-7-chloro-2-aminoquinoline.
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Prior to in vivo examination, compound toxicity was examined by
treating uninfected mice with 160 mg/kg/day (the highest admin-
istered dose) of each compound for three consecutive days. A drug
was considered non-toxic if mice did not develop any gross clini-
cal symptoms (ruffled fur, lethargy or weight loss) during a 30-
day observation period. Compounds determined to be non-toxic were
evaluated for antimalarial efficacy at doses of 80 mg/kg/day and
160 mg/kg/day. Compound efficacy was evaluated based on
parasitaemia over time and survival of treated versus untreated mice.
Cure was defined as survival past Day 31 post-infection (p.i.) and
complete clearance of parasitaemia. Survival past Day 31 p.i. with
residual parasitaemia indicated survival without cure. If a com-
pound did not afford survival but significantly prolonged time to
death of treated versus untreated mice (P < 0.05), the effect was
defined as prolonged survival. Finally, if a compound cured mice
at a dose of 80 mg/kg/day, efficacy was tested at lower doses, in-
cluding 40, 20 and 10 mg/kg/day. Parasitaemia was determined twice
weekly starting from Day 3 p.i. (immediately before treatment) and
only mice in which parasitaemia was detected were submitted to
experimental treatment. Parasitaemia was evaluated by microscop-
ic examination of Giemsa-stained thin blood smears prepared from
mouse tail blood on a Zeiss Axioscope 2+ optical microscope at 1000×
magnification, whilst parasite clearance was additionally con-
firmed in treated survivors by quantitative PCR (qPCR).
2.5. In vitro examination of compound efficacy
In vitro testing was performed using a LDH assay. Compounds
were first screened at a concentration of 500 nM and those that
showed a minimum of 50% growth inhibition of parasites of either
strain (3D7 or Dd2) were further examined to obtain the IC50 value.
Three independent experiments were performed for each com-
pound, each with three replicates per condition. The assay was
performed in flat-bottom 96-well microtitre plates. Briefly, com-
pounds were tested at eight different concentrations ranging from
2 nM to 256 nM, plated in a volume of 100 μL. Parasites were plated
into the wells while in the ring phase at 0.75% haematocrit and 2%
parasitaemia in a volume of 100 μL. Each well contained the com-
pound and parasite culture in a final volume of 200 μL. Following
incubation at 37 °C for 48 h in a HeracellTM 150i incubator (Thermo
Scientific, Waltham, MA), parasites were harvested and were sub-
jected to three 20-min freeze–thaw cycles to resuspend the culture.
Cultured erythrocytes without drug were used as the assay blank,
whilst infected erythrocytes without drug were used as the assay
control. CQ was used as the positive control for drug efficacy. To ini-
tiate the LDH reaction, 120 μL of the detection reagent mixture
(Malstat and NBT/PES) was aliquoted into a new flat-bottom 96-
well microtitre plate to which a 20 μL sample of each parasite culture
was added. Colour development of the LDH plate was detected using
a Multiskan® X microplate reader (Thermo Scientific) at 620 nm fol-
lowing 1 h of incubation in the dark. All reagents used in the assay
were purchased from Sigma-Aldrich Inc. (St Louis, MO).
2.6. In vivo examination of compound efficacy
Antimalarial activity in vivo was tested by the modified Thomp-
son test [22]. Infected erythrocytes were obtained from the peripheral
blood of a donor mouse infected with P. berghei. Mice were inocu-
lated intraperitoneally with 106 infected erythrocytes diluted in
phosphate-buffered saline (PBS) to a total volume of 250 μL (Day
0). Mice were treated with the investigational compounds once a
day for three consecutive days (Days 3, 4 and 5 p.i.). All com-
pounds were administered p.o. at doses ranging from 10 mg/kg/
day to 160 mg/kg/day in a total volume of 200 μL. Survival and
parasitaemia were monitored for 30 days p.i. Parasitaemia was evalu-
ated by microscopic examination of thin blood smears.
2.7. PCR
Residual parasitaemia was examined in the surviving mice by
the real-time qPCR method adapted from Rougemont et al based
on detection of the Plasmodium species-specific 18S rRNA gene [23].
Briefly, mice alive past day 31 p.i. and with complete parasite clear-
ance were sacrificed and blood (300–500 μL) was sampled from the
left ventricle of the heart. The liver was removed, was rinsed with
Dulbecco’s PBS and was homogenised. DNA extraction was per-
formed using 100 μL of blood and liver homogenate samples using
a DNeasy® Blood and Tissue Kit (QIAGEN, Hilden, Germany) ac-
cording to the manufacturer’s instructions. Each PCR reaction
contained 1 × MaximaTM Probe qPCR Master Mix (Thermo Fisher Sci-
entific), 200 nM of each primer, 50 nM probe, 1 U of UNG (Thermo
Fisher Scientific) and 3 μL of template DNA in a final volume of 20 μL.
PCR conditions were as follows: one holding step at 50 °C for 2 min;
one holding step at 95 °C for 10 min; followed by 45 cycles of 95 °C
for 15 s and 60 °C for 1 min. Samples with Ct values >40 were con-
sidered negative. A positive (P. berghei DNA) and a negative (H2O)
control were included in each run.
2.8. Statistical analysis
IC50 values were obtained using a sigmoidal dose–response model
with the variable slope fitted to the results. Survival rates in each
particular group were estimated by the Kaplan–Meier product limit
method and were compared by the log-rank (two curves) and log-
rank for trends (three or more curves) tests. The level of statistical
significance was 0.05. Statistical analysis was performed using
GraphPad Prism v.5 (GraphPad Software Inc., La Jolla, CA).
3. Results
A series of 26 aminoquinolines was examined in this work. Of
these, 12 compounds inhibited proliferation of either the CQS or CQR
Plasmodium strain by ≥50%; the remaining 14 compounds did not
and thus were eliminated from further study.
All 12 compounds were first assayed for toxicity. Four com-
pounds (AQ2, AQ3, ClAQ3 and ClAQ6) were shown to cause acute
toxicity at a dose of 160 mg/kg/day, three of which were elimi-
nated from further in vivo examination. However, due to chemical
similarity with other members of the benzothiophene group, which
were non-toxic even at the highest applied dose, one of the latter
compounds (ClAQ3), although toxic at 160 mg/kg/day, was further
tested for toxicity at 80 mg/kg/day and was found to be non-toxic
at this dose. ClAQ3 was thus included in the in vivo examination
(Table 2).
A total of nine compounds (AQ1, ClAQ1, ClAQ2, ClAQ3, ClAQ4,
ClAQ5, FAQ1, FClAQ1 and FClAQ2) were subjected to in vivo testing.
When administered at doses of 80 mg/kg/day and/or 160 mg/kg/
day, all nine compounds significantly prolonged survival of treated
versus untreated mice (P < 0.05; Figs 1 and 2).
Remarkably, three ClAQ compounds (ClAQ1, ClAQ4 and ClAQ5)
and one FClAQ compound (FClAQ1) (chemical structures pre-
sented in Table 3) afforded survival of 60–100% of treated mice past
Day 31. Of these, ClAQ4 and ClAQ5 afforded a 60–80% survival rate
of infected mice, although not even the highest dose of either com-
pound eradicated parasitaemia in a single animal.
However, treatment with 80 mg/kg/day and 160 mg/kg/day of
the other two compounds (ClAQ1 and FClAQ1) afforded complete
cure. All treated infected mice survived beyond Day 31 (Figs 3 and
4) and, moreover, survival was associated with parasite clearance
as determined by microscopic examination and by qPCR of murine
blood and liver tissues after Day 31. Thus, we next examined their
effect at lower doses, which revealed a strong dose-dependent effect
(P = 0.0141 and P = 0.0362 for ClAQ1 and FClAQ1, respectively), but
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did not afford survival. ClAQ1 is particularly interesting in this respect
as treatment with even the lowest dose (10 mg/kg) prolonged sur-
vival (P = 0.0031). However, dose reduction resulted in persistence
of parasitaemia in all mice.
On the other hand, an interesting observation with FClAQ1 was
that although all mice treated with 40 mg/kg/day eventually suc-
cumbed to the infection, they were able to tolerate very high levels
of parasitaemia, which amounted up to 62% (range 37.5–62.4%). In
contrast, the highest level of parasitaemia observed with any other
treatment regimen ranged from as low as 0.1% to not more than
13.9% (Table 4).
Interestingly, the correlation between the in vivo and in vitro
results appeared indiscriminate (Table 2). The four compounds with
the highest in vivo efficacy did not show the best in vitro results,
i.e. the lowest IC50 values for both strains. For instance, ClAQ4 and
ClAQ5, the two compounds that afforded survival but not cure, had
quite low IC50 values and by far the lowest ones against the CQR strain.
In contrast, FClAQ1, which cured all infected mice (in two doses),
had no in vitro effect against the CQR strain (>500 nM). On the other
hand, AQ1, the single compound that had lower IC50 values than CQ
against both strains, did not have remarkable in vivo efficacy. Of the
remaining four compounds, which all significantly prolonged the
Table 2
Antimalarial effect of experimental aminoquinolines examined in vitro and in vivo.
Group Compound In vitro LDH assay
[GM IC50 value (nM)]
In vivo Thompson test
Strain 3D7 a Strain Dd2 b Toxicity at 160 mg/kg/day Treatment dose (mg/kg/day) Effect on Day 31 p.i.
AQ AQ1 14.08 118.2 NT 80 Prolonged time to death * (P = 0.0031)
AQ2 99.86 195.3 T
AQ3 67.33 223.0 T
ClAQ ClAQ1 34.75 58.4 NT 160, 80 100% cure
40, 20, 10 Prolonged time to death * (P = 0.0031, 0.0067, 0.0031)
ClAQ2 142.70 >500 NT 80 Prolonged time to death * (P = 0.0031)
ClAQ3 43.48 34.8 T 80 Prolonged time to death * (P = 0.0067)
ClAQ4 32.53 13.7 NT 160 75% survival c (P = 0.0067)
80 80% survival c (P = 0.0031)
ClAQ5 34.13 16.7 NT 160 60% survival c (P = 0.002)
ClAQ6 67.07 35.9 T
FAQ FAQ1 185.38 >500 NT 80 Prolonged time to death * (P = 0.0290)
FClAQ FClAQ1 41.13 >500 NT 160, 80 100% cure
40 Prolonged time to death * (P = 0.0031)
20, 10 N/S (P > 0.05)
FClAQ2 145.36 >500 NT 160 Prolonged time to death * (P = 0.0020)
Control CQ 18.74 249.1 NT 160 100% cure
LDH, lactate dehydrogenase; GM, geometric mean; IC50, 50% inhibitory concentration; p.i., post-infection; AQ, 4-aminoquinoline; ClAQ, 7-chloro-4-aminoquinoline; FAQ, 3-
fluoro-4-aminoquinoline; FClAQ, 3-fluoro-7-chloro-4-aminoquinoline; CQ, chloroquine; NT, non-toxic; T, toxic; N/S, not significant.
* Versus infected untreated (control) mice.
a CQ-sensitive Plasmodium falciparum strain 3D7.
b CQ-resistant P. falciparum strain Dd2.
c With residual parasitaemia.
Fig. 1. Effect of a 3-day treatment with 160 mg/kg/day of the investigational com-
pounds on the survival of mice infected with Plasmodium berghei ANKA strain. ,
treatment days.
Fig. 2. Effect of a 3-day treatment with 80 mg/kg/day of the investigational com-
pounds on the survival of mice infected with Plasmodium berghei ANKA strain. ,
treatment days.
Table 3
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survival time of treated infected mice, three had much higher IC50
values than CQ against both parasite strains (Table 2).
4. Discussion
Here we present the antimalarial efficacy of a series of investi-
gational aminoquinoline compounds. Of the 12 compounds that
exhibited ≥50% growth inhibition in parasite cultures, the efficacy
of nine compounds shown to be non-toxic in vivo was examined
in a mouse infection model. When given in three daily doses of
80 mg/kg or 160 mg/kg, all nine compounds significantly pro-
longed survival compared with untreated controls, but most notably,
four compounds afforded survival of mice past Day 31. Of these, com-
pounds ClAQ4 and ClAQ5 afforded a high protection rate although
with residual infection in mice that survived the observation period,
whilst compounds ClAQ1 and FClAQ1 afforded cure (with parasite
clearance) for 100% of mice at doses both of 160 mg/kg/day and
80 mg/kg/day. At the latter dose, the survival rate afforded by ClAQ1
and FClAQ1 was even superior to that of CQ. Furthermore, these two
compounds showed significant activity at lower doses as well, of
which ClAQ1 prolonged time to death (versus untreated controls)
even at a dose as low as 10 mg/kg.
Several important observations arise from these data. First, we
have observed that the best in vivo effects did not correlate with
in vitro efficacy. For instance, AQ1 was the single compound that
had lower IC50 values than CQ against both strains, but its in vivo
efficacy did not go beyond prolonging survival of infected treated
mice. On the other hand, none of the three examined compounds
with fluorine on the aminoquinoline moiety had any effect of against
the CQR strain in vitro, yet all significantly prolonged survival of in-
fected treated mice, whilst FClAQ1 even afforded complete cure. Such
discordance has been previously reported for some thiophene- and
furan-based aminoquinolines synthesised by the same group [24].
The discrepancy between in vitro and in vivo effects suggests that
the antimalarial efficacy of such compounds is due to their me-
tabolites rather than the compounds themselves.
The second interesting observation was that although FClAQ1
at lower doses did not afford survival, it allowed mice to survive
Fig. 3. Effect of a 3-day treatment with ClAQ1 in the full dosage regimen on the sur-
vival of mice infected with Plasmodium berghei ANKA strain. , treatment days.
Fig. 4. Effect of a 3-day treatment with FClAQ1 in three dosage regimens (40, 80
and 160 mg/kg) on the survival of mice infected with Plasmodium berghei ANKA strain.
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remarkably high parasite burdens (37–62%), as opposed to the
highest parasitaemia of only 14% appearing to be the survival limit
by any other treatment. Importantly, this compound (designated
compound 25 in [19]) has been shown to have significant activity
in the plasmodial liver stage infection [19], where the
intrahepatocytic inhibition of parasite growth was attributed to
the presence of the fluorine atom at the C(3) position on the
aminoquinoline moiety. The ability of mice treated with this com-
pound to survive massive parasitaemia may indicate its impact on
parasite pathogenicity/virulence.
Importantly, the approach taken in this study, i.e. to examine all
compounds that exerted ≥50% parasite growth inhibition in vitro
in parallel with their effects in an in vivo infection model, allowed
us to observe a therapeutic potential that would have gone unno-
ticed had we chosen the usual approach to examine in vivo only
those compounds with an IC50 lower than that of the control drug.
This observation also suggests that there may have been drug can-
didates in the past that have been missed because of the approach.
It is to be hoped that highly advanced techniques including high-
throughput technologies will help avoid such unfortunate events
in the future.
A look at the chemical structures of the four most effective com-
pounds (Table 3) shows that the carrier in ClAQ4 and ClAQ5 is
benzothiophene, whilst in the case of ClAQ1 and FClAQ1 it is
adamantane. Since the results showed that both compounds with
adamantane afforded cure of mice, it appears that the higher in vivo
activity may be attributed to its use as a carrier. Among its many
biological properties, adamantane has been shown to substantial-
ly increase drug solubility in lipophilic membranes and may thus
increase compound uptake [25].
In summary, the results presented here illustrate the enor-
mous potential of aminoquinoline derivatives bearing an adamantane
group as antimalarials whose metabolites and mechanisms of action
warrant further investigation and put adamantane into the spot-
light as a carrier that enhances the antimalarial effect of
aminoquinolines.
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